Diagnostic value of immunohistochemistry on formalin-fixed, paraffin-embedded skin biopsy specimens for bullous pemphigoid. by Glauser, S et al.
Diagnostic value of immunohistochemistry on formalin-fixed 
paraffin-embedded skin biopsy specimens for bullous pemphigoid 
 
Running title 
Immunohistochemistry studies for the diagnosis of bullous pemphigoid 
 
 
S.Glauser1, M. Rutz1 , S. Cazzaniga1,2, I. Hegyi1, L. Borradori1, H. Beltraminelli1 
 
1 Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, 
Switzerland 
2 Centro Studi GISED, Bergamo, Italy 
 
 
 
 
Address for correspondence 
Helmut.Beltraminelli@insel.ch   
Luca.Borradori@insel.ch 
Department of Dermatology 
Inselspital, Bern University Hospital  
University of Bern 
CH-3010 Bern.    
+41 31 632 05 55 
 
Funding 
 None 
 
Conflict of interest 
 None declared 
 
What’s already known about this topic?  
 Direct immunofluorescence microscopy (DIF) studies represent the gold standard for the 
diagnosis of bullous pemphigoid (BP). 
 Recent studies have reported that immunohistochemistry techniques using formalin-fixed, paraffin-
embedded skin biopsy specimens are able to detect tissue-bound immunoreactants in BP with 
high sensitivity and thus constitute an alternative and practical diagnostic tool. 
 
 
What does this study add?  
 Immunohistochemical analyses are not sensitive enough to recommend their use for the diagnosis 
of BP, since less than 50% of 51 consecutive paraffin-embedded skin biopsy specimens obtained 
from patients with newly diagnosed BP were positive.  
 If DIF cannot be performed, immunohistochemistry represents a useful diagnostic tool only in 
presence of histologically subepidermal blistering and/or with positive immunoserological tests , 
which are associated with a better sensitivity. 
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Abstract 
 
Background: Direct immunofluorescence microscopy (DIF) studies constitute the gold standard for 
the diagnosis of bullous pemphigoid (BP), but depend on the availability of specialized laboratories 
and often on an additional skin biopsy specimen. 
Objective: To assess the value of immunohistochemical analyses (IHCA) in the diagnosis of BP using 
formalin-fixed, paraffin-embedded skin biopsy specimens as alternative to DIF. Furthermore, to study 
the correlation between the results of IHCA and the presence of histological subepidermal blister 
formation and of circulating autoantibodies by indirect immunofluorescence (IIF) studies using split-
skin and or by ELISAs. 
Methods: We included all newly diagnosed BP patients evaluated between 2008 and 2010. There 
were 51 consecutive skin biopsy specimens obtained from 38 BP patients with positive DIF.  
Results: By IHCA diagnostic deposits of immunoreactants were found in 45.1% of all tested cases. 
Deposits of C3d, IgG, IgM, IgE and IgA were found in 37.3%, 23.5%, 2%, 0%, and 0% of cases, 
respectively. Deposits of C3d and/or IgG were found in 79.2% of the 24 cases with a blister and in 
83% of the 12 cases with subepidermal blistering and positive immunoserological analyses, 
respectively. 
Conclusion: In contrast to previous studies, our findings in an unselected patient cohort, indicate that 
IHCA are not sufficiently sensitive to replace DIF studies for confirming the diagnosis of BP. IHCA 
sensitivity significantly increases in the presence of histological blistering and/or of circulating 
autoantibodies. IHCA represents a potential rescue diagnostic technique only if specialized 
laboratories and/or a second biopsy specimen for DIF are unavailable. 
 
 
Key words: bullous pemphigoid, direct immunofluorescence, immunohistochemistry, C3d, IgG 
 
Introduction 
 
Bullous pemphigoid (BP) is the most frequent autoimmune subepidermal blistering disease of the skin 
and mucosae. It is characterized by the presence of IgG autoantibodies directed against the BP 
antigen 230 (BP230, epithelial isoform of BPAG1) and the BP antigen 180 (BP180, BPAG2 or type 
XVII collagen), two components of hemidesmosomes in stratified epithelia.
1,2 
Ample evidence exists 
indicating that IgG anti-BP180 autoantibodies are pathogenic by triggering an inflammatory cascade 
that leads to tissue damage and subepidermal blister formation.
1-3 
BP predominantly affects elderly patients and typically presents with widespread vesicles and bullae, 
together with urticarial plaques and eczematous lesions. Nevertheless, excoriations, prurigo-like, 
eczematous, and/or urticarial lesions may constitute the only signs of the disease.
4
 
Diagnosis of BP is based on a combination of criteria, including compatible clinical features, 
histological, and direct immunofluorescence (DIF) microscopy findings.
6
 Since clinical and 
histopathological features may be nonspecific, a positive DIF of a perilesional skin biopsy specimen is 
required for diagnosis.
6
 The latter shows linear deposits of IgG, C3, and, more rarely, IgA and/or IgE 
immune deposits along the epidermal basement membrane zone (BMZ).
1,2,7,8
 Proper classification of 
BP often requires the detection of circulating autoantibodies by either indirect immunofluorescence 
(IIF) microscopy using NaCl-separated normal human skin or by ELISA-BP180 and/or ELISA-BP230.
6
  
Although DIF studies represent the golden standard for the diagnosis of BP, they often pose a number 
of disadvantages, such as the necessity of obtaining a second biopsy, rapid transport of the sample, 
specialized technical processing, and, finally, a relatively high cost.
9
 For these reasons, a few studies 
have recently assessed the value of immunohistochemistry analyses (IHCA) on paraffin-embedded 
tissue as alternative for the diagnosis of autoimmune bullous skin diseases.
10-14
 In other immune-
mediated diseases, such as renal diseases, IHCA already constitute a well-established diagnostic 
procedure.
15-17
 
In this retrospective study, we have systematically assessed the value of IHCA using paraffin-
embedded skin biopsy specimens obtained from all newly diagnosed cases of BP evaluated over 
three years.  
 
Material and Methods 
Patients and diagnostic criteria. In this monocentric retrospective study we systematically included all 
biopsy specimens obtained from patients with a new diagnosis of BP, evaluated in our tertiary referral 
centre between January 2008 and December 2010. Diagnosis of BP was based on the following 
widely accepted criteria: (i) compatible clinical features (excoriated, eczematous, urticarial and/or 
bullous lesions) associated with itch; (ii) deposits of IgG and/or C3c along the epidermal side of the 
basement membrane by DIF microscopy studies; (iii) presence of circulating autoantibodies binding to 
the epidermal side or both the epidermal and dermal side of NaCl-separated normal human skin by IIF 
microscopy; alternatively, presence of anti-BP180 and ⁄or anti-BP230 IgG autoantibodies by ELISA 
(MBL, Nagoya, Japan); and (iv) in case that criterion (iii) was either negative or if patient’s serum was 
not available, diagnosis was based on the presence of 3 of 4 validated clinical criteria for BP.
5
 
Skin biopsy specimens obtained from patients diagnosed with Grover’s disease, Hailey-Hailey 
disease, Darier’s disease, cutaneous lupus erythematosus, lichen planus, toxic epidermal necrolysis, 
drug reactions, erythema multiforme and Sweet syndrome were used as controls (total n=28).  
Immunohistochemical staining. Immunohistochemical stainings were carried out on formalin-fixed 
paraffin-embedded skin tissue samples processed using the Leica Bond Max autostainer (Leica, 
Germany). For this purpose, 4µm-thick sections on star frost slides (Knittel Glass, Germany) were 
used. Pretreatment: C3d and IgE: Bond Pretreatment Kit (AR9551) followed by Bond Epitope 
Retrieval Solution 2 (AR9640). IgG and IgM, first unmasked in EDTA solution. IgA: citrate solution. 
The used primary antibodies included: rabbit polyclonal anti-human C3d antibody (Abcam, No. 
ab15981), dilution 1:600; rabbit polyclonal anti-IgG antibody (Cell Marque, CMC26911021), dilution 
1:1500; mouse monoclonal anti-human IgA antibody (Novocastra, NCL- L- IgA), dilution 1:600; mouse 
monoclonal anti-human IgM antibody (Novocastra NCL-L-IgM), dilution 1:800; rabbit polyclonal anti-
human IgE antibody (Diagnostic BioSystems, No RP-022-05), dilution 1:100.  
In analogy to the approach used for the evaluation of DIF, presence of continuous linear deposits of 
immunoreactants along the epidermal BMZ, was required to consider the results of IHCA as positive, 
whereas the presence of discontinuous granular immune deposits along the epidermal BMZ was 
considered not diagnostic. IHCA were independently evaluated by three investigators (SG, HB and 
IH). Tissue specimens obtained from tonsils or B-cell lymphoma containing germinal centres and 
plasma cells were also tested by IHCA and used as positive controls (positivity of C3d in germinal 
centres and of immunoglobulin in plasma cells). 
For direct IF microscopy studies, the method and reagents used are described elsewhere
8
. 
Statistical analysis. Data are presented as either means with standard deviations (SD) or as numbers 
with percentages for continuous and categorical variables, respectively. The impact on IHCA results of 
demographical variables, histological blistering, IIF and ELISAs was assessed by using univariate 
generalized linear models with repeated measure design with appropriate and logit link function. The 
association was expressed in terms of odds ratios (OR) along with their 95% confidence interval (CI) 
and p-values. In case of zero frequency, a continuity correction was used to compute OR and the 
Pearson’s Χ
2
 test was used to compute p-value. All tests were considered significant at p <0.05. 
Analyses were performed with SPSS ver. 20 (IBM Corp). 
 
Results  
A total of 51 skin biopsy specimens obtained from 38 patients with newly diagnosed BP over a three-
year period were included. The mean age of the patients was 76.5 years (range 48-94 years) and 
there were 18 males and 20 females. In 29, 7, and 2 patients, there were 1, 2 and 4 formalin-fixed skin 
biopsy specimens available for testing, respectively. 
 
All patients had positive DIF microscopy studies with detection along the epidermal BMZ of linear 
deposits of C3c, IgG, IgM, IgE, and/or IgA in 88.2%, 52.9%, 21.6%, 17.6% or 11.8% of cases, 
respectively (Table 1). 
 
By IHCA linear deposits of C3d, IgA, IgE, IgG, and or IgM were found along the epidermal BMZ in 23 
of 51 (45.1%) specimens (Table 1).  
Specifically, positive IHCA with C3d were observed in 19 of 51 (37.3%) specimens (Figure 1). 
Furthermore, in the 6 biopsy specimens obtained from patients, in which DIF studies for C3c were 
negative, IHCA was also systematically negative. 
Diagnostic linear deposits of IgG were observed in 12 of the 51 (23.5%) skin specimens by IHCA. 
Noteworthy, when only the cases, which were positive for IgG deposits by DIF were analysed by 
IHCA, only 7 of 27 (25.9%) were also positive. Furthermore, in the 24 biopsy specimens obtained from 
patients, in which DIF studies for IgG were negative, IHCA was positive in 5 cases. 
With regard to other immunoreactants (IgM, IgA, IgE), the results were almost invariably negative by 
IHCA. Linear IgM deposits were found only in one out of 51 (2%) tested skin specimens, whereas 
search for IgA and IgE deposits was always negative. In the one case in which linear deposits of IgM 
were found by IHCA , DIF was also positive. 
As controls, we tested 18 formalin-fixed, paraffin-embedded skin biopsy specimens obtained from 
patients presenting with different types of inflammatory cutaneous reactions. In all these cases, IHCA 
did not disclose any immune deposit. Furthermore, IHCA of tissue specimens obtained from tonsils or 
B-cell lymphoma with germinal centres and plasma cells showed positivity of C3d in germinal centres 
and of immunoglobulin in plasma cells. 
Next, we assessed whether the IHCA results were affected by the presence of distinct parameters, 
such as age and gender of affected patients, presence of histological blistering, positive IIF 
microscopy findings and/or positive ELISA-BP180 and/or ELISA-BP230. 
First, age older than 75 years or gender did not affect the IHCA results (Table 2). Next, when the 24 
skin biopsy specimens in which histologically subepidermal blister formation was observed were 
tested, there was a statistically significant increase (p-value: <0.001) in the detection rate of immune 
deposits by IHCA. In fact, among the latter, 19 of 24 cases (79.2%) showed positive results with either 
C3d and/or IgG when compared to only 4 (14.8%) of the 27 tissue specimens without histological 
blistering. Specifically, C3d deposits were found in 15 (62.5%) of 24 cases with histological blistering, 
while IgG in 12 (50%) of them (Table 2).  
Nineteen of the 27 (70.4%) tested BP sera were positive by IIF microscopy studies using salt-split 
normal human skin. When the corresponding biopsy specimens were tested by IHCA, the positive rate 
of IHCA also significantly increased (p-value: 0.03). In fact, 14 (73.7%) of these 19 cases were 
positive. Specifically, 12 of these 14 cases were positive for C3d, 7 cases positive for IgG and 5 cases 
positive for both IgG and C3d. In contrast, only 2 (25%) of the 8 biopsy specimens obtained from BP 
patients with negative IIF were positive by IHCA. Search for circulating autoantibodies by ELISA-
BP180 and/or ELISA-BP230 was performed in 32 cases, 21 (65.6%) of which were positive (Table 2). 
Fourteen (66,6%) of these 21 cases showed positive findings by IHCA with either C3d (12 of 14 
cases), IgG (8 cases), or both IgG and C3d deposits (6 cases). When the biopsy specimens obtained 
from the 16 BP cases in which both IIF and ELISAs were positive, 12 cases (75%) were positive by 
IHCA with either C3d (10 cases), IgG (7 cases) or both IgG and C3d deposits (5 cases). The rate of 
positive IHCA was thus significantly increased (p-value: 0.03) when compared to the 12 probes 
obtained from BP patients with both negative IIF and ELISAs, which were positive in only 4 cases 
(33%). Finally, the rate of IHCA positivity was the highest when skin specimens obtained from patients 
with histological blistering and with both positive IIF and ELISAs were tested. In fact in the latter cases 
IHCA was positive in 83.3% of the 12 tissue samples, whereas only 7 of 31 (22.6%) cases lacking 
these characteristics were positive. The difference was again statistically significant (p-value: 0.002) 
(Table 2). Noteworthy, presence of histological blistering, positive IIF microscopy findings and/or 
positive ELISA-BP180 and/or ELISA-BP230 significantly affected the positivity of IHCA even when 
reactivity with either IgG or C3d was analysed separately (data not shown). 
 
Discussion 
We have assessed the value of IHCA in the diagnosis of BP using formalin-fixed paraffin-embedded 
skin biopsy specimens obtained from all BP cases diagnosed consecutively over three years in our 
centre. The ability of IHCA to detect the presence of linear deposits of immunoreactants along the 
epidermal BMZ was retrospectively compared to that of DIF microscopy studies, the positivity of which 
is essential and required for the diagnosis of BP.
6
  
Our study, which represents the largest series available so far, indicates that the sensitivity of IHCA is 
poor when compared to that of DIF. In fact, by IHCA only 45.1% of 51 skin biopsy specimens showed 
positive diagnostic findings, whereas all included cases (100%) were positive by DIF as obligatory 
inclusion criterion (Table 1). Specifically, IHCA demonstrated the presence of C3d, IgG and IgM in 
only 37.3%, 23.5% and 2% of cases, respectively, whereas deposits of either IgA or IgE were not 
observed in any of 51 tested biopsy specimens. Hence, the number of positive samples by IHCA was 
invariably lower compared to that obtained by DIF for all tested immunoreactants (Table 1). 
Furthermore, IHCA were never able to detect the presence of distinct specific immunoreactants such 
as IgG or C3d in samples obtained from subjects, in which the corresponding DIF microscopy studies 
were negative for those reactants. 
We further assessed factors potentially affecting the results of IHCA (Table 2). While age of BP 
patients and gender did not have an impact on IHCA positivity, the latter significantly increased using 
skin biopsies showing histologically subepidermal blister formation. In fact, almost 80% of the 24 
tissue samples with subepidermal blistering were positive for either C3d and/or IgG by IHCA. 
Furthermore, in skin biopsy specimens obtained from patients with circulating IgG autoantibodies as 
detected by either ELISA (ELISA-BP180 and/or ELISA-BP230) and/or by IIF, the sensitivity of IHCA 
also increased, since diagnostic deposits of immunoreactants were found in up to 75% of tissue 
specimens (Table 2). These rates were thus significantly higher compared to those obtained using 
tissue samples from seronegative patients (Table 2). Finally, in the cases, in which there were both 
histological subepidermal blistering and positive immunoserological findings by either ELISAs and/or 
IIF, the percentage of positive IHCA results were the highest, since 83.3% of 12 cases showed 
positive IHCA with at least C3d and/or IgG deposits (Table 2). 
Another recent IHC study similarly reports the detection of diagnostic linear deposits of C4d in 86% of 
29 skin biopsies obtained from BP patients. Again the majority of the included cases (>70%) showed 
histologically subepidermal blister formation. 
18 
The results obtained in our series with an unselected group of newly diagnosed BP patients over a 
three-year period are hence at variance with those from 4 previous studies.
10-13 
The latter reported 
sensitivities of 70% to 100% of IHCA when compared to DIF as well as a high concordance of the 
results between IHCA and DIF. For example, Magro et al. found linear deposits of C3d and of C4d 
staining in 100% and in 23.5% of the formalin-fixed, paraffin-embedded tissue samples obtained from 
BP patients, respectively.
10
 Pfalz et al. found diagnostic linear deposits of C3d in 97% of the 32 
studied cases of BP.
11
 Chandler et al. analysed 10 biopsy specimens obtained from either BP or 
epidermolysis bullosa acquisita patients.
12
 In 7  (70%) of these 10 cases, they detected C4d deposits 
along the epidermal BMZ. Finally, in a retrospective series, Kwon et al. also found the presence of 
diagnostic deposits of C4d in 10 (83%) of 12 patients with BP as well as in 8 (100%) out of 8 patients 
with gestational pemphigoid.
13
 At least two factors may account for the low positive rate of IHCA in our 
study when compared to previous reports. First, the latter have most likely encompassed selected BP 
patients with cutaneous blistering and high disease activity. In the study of Pfalz et al.
11
, at least 75% 
of the included patients showed clinically and/or histological blistering. In the study of Chandler et al.
12
 
three of the 7 positive patients also had subepidermal blister formation. In this study, diagnosis of BP 
was not confirmed by immunoserological criteria in 5 cases. In the remaining two studies details about 
clinicopathological features were not provided.
10,13
 Two recent studies have shown that at least 20% of 
patients with BP do not present clinically with obvious skin blistering at time of diagnosis.
 4,19
 These 
patients are reasonably expected to exhibit a reduced amount of tissue-bound autoantibodies, since 
levels of circulating IgG autoantibodies to BP180 usually correlate with disease severity.
1,2,6
 Hence, 
the inclusion of BP patients with clinically blistering and high disease activity is likely to represent a 
selection bias accounting for the previously described high sensitivity of IHCA in BP. In contrast, we 
assessed tissue samples obtained from an unselected cohort of patients with newly diagnosed BP.  
The inclusion of selected samples in previous immunopathological studies of BP, such as for testing 
the diagnostic value of the ELISA-BP180, has invariably resulted in exaggerated high sensitivity, 
which could not be later confirmed when consecutive serum samples were tested.
1
 
Another factor potentially explaining the lower positivity rate of our IHCA is the use of a different 
protocol with other second-step antibodies and reagents. It is well possible that our protocol for IHCA 
can be improved to increase its sensitivity. Nevertheless, it is unlikely that a technical problem 
accounts for the low detection rate found in our study. In fact, the positivity of IHCA in patients with 
histological blistering and/or circulating autoantibodies was similarly high as that described in previous 
reports. The range of sensitivity is comparable to the lower end of the previously published results. 
In our study DIF was able to detect the presence of linear deposits of IgA along the epidermal BMZ in 
up to 12% of the tested biopsy specimens. In contrast, all cases studied by IHCA were negative. Since 
the presence of tissue-bound IgA deposits is a critical diagnostic criterion for both linear IgA bullous 
dermatosis and dermatitis herpetiformis, the diagnostic value of IHCA in these two diseases with 
features potentially mimicking BP is particularly questionable and limited. The inability to detect linear 
deposits of IgE by IHCA was also somehow unexpected. Evidence exists indicating that the detection 
of tissue-bound IgE is of diagnostic utility in BP and that anti-BP180 IgE autoantibodies contribute to 
tissue damage.
8,20,21
  
In conclusion, our results in an unselected cohort of BP patients indicate that IHCA is not sufficiently 
sensitive to replace DIF microscopy studies for the immunopathological diagnosis of BP. The 
sensitivity of IHCA for detection of either IgG and/or C3d deposits is less than 50% when compared to 
DIF microscopy studies. Hence, IHCA cannot be proposed as standard procedure for confirming the 
diagnosis of BP patients in the daily routine. Nevertheless, if either specialized immunopathological 
laboratories or appropriate biopsy specimens for DIF are not available, IHCA may be a useful rescue 
method, particularly in cases showing histologically subepidermal blistering and/or with positive 
immunoserological tests.  
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Tables 
 
Table 1. Survey of the results observed by both direct immunofluorescence microscopy (DIF) 
studies and immunohistochemical analysis  (IHCA) for the various immunoreactants.   
 
Methods 
Positive results / 
all cases  (%) C3 IgG IgA IgM IgE 
DIF  
51/51 *              
(100%) 
45/51 
(88.2%) 
27/51 
(52.9%) 
6/51 
(11.8%) 
11/51 
(21.6%) 
9/51 
(17.6%) 
IHCA  
23/51              
(45.1%) 
19/51 
(37.3%) 
12/51 
(23.5%) 
0/51  
(0.0%) 
1/51      
(2%) 
0/51   
(0%) 
 
 
* As for inclusion, all studied tissue samples were obtained from patients showing positive 
findings with at least one immunoreactant by DIF studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Summary of the results obtained by IHCA according to a number of different parameters with statistical assessment of their 
impact on the detection rate of either C3d and or IgG deposits along the epidermal basement membrane zone. 
 
 
 
N, total number of samples per category;  IHC, immunohistochemical analyses; n, number of positive samples; OR, odds ratio; CI, confidence 
interval; p, p-value; Histology, presence of histological blistering;  -, negative results; +, positive results; ELISA, either ELISA-BP180 and or 
ELISA-BP230; IIF, indirect immunofluorescence microscopy studies using NaCl-separated normal human skin; OR and p-values were computed, 
 
N Any IHC + OR (95% CI) p C3d+ OR (95% CI) p IgG+ OR (95% CI) p 
n % n % n % 
Age (yrs) < 75 25 10 40.0% 1  9 36.0% 1  3 12.0% 1  
75+ 26 13 50.0% 1.50 (0.50 - 4.55) 0.47 10 38.5% 1.11 (0.36 - 3.46) 0.86 9 34.6% 3.88 (0.91 - 16.58) 0.07 
Gender M 25 14 56.0% 2.40 (0.78 - 7.44) 0.13 11 44.0% 1.77 (0.56 - 5.57) 0.33 9 36.0% 4.31 (1.01 - 18.46) 0.05 
W 26 9 34.6% 1  8 30.8% 1  3 11.5% 1  
Histology - 27 4 14.8% 1  4 14.8% 1  0 0.0% 1  
+ 24 19 79.2% 21.85 (5.13 - 93.00) <0.001 15 62.5% 9.58 (2.45 - 36.8) 0.001 12 50.0% 55.00 (3.01 - 1004.28)* <0.001 
IIF - 8 2 25.0% 1  1 12.5% 1  1 12.5% 1  
+ 19 14 73.7% 8.40 (1.26 - 56.07) 0.03 12 63.2% 12.00 (1.21 - 118.89) 0.03 7 36.8% 4.08 (0.41 - 40.45) 0.23 
ELISA - 11 3 27.3% 1  2 18.2% 1  1 9.1% 1  
+ 21 14 66.7% 5.33 (1.07 - 26.61) 0.04 12 57.1% 6.00 (1.03 - 34.84) 0.04 8 38.1% 6.15 (0.66 - 57.59) 0.11 
IIF + ELISA - 12 4 33.3% 1  3 25.0% 1  1 8.3% 1  
+ 16 12 75.0% 6.00 (1.15 - 31.23) 0.03 10 62.5% 5.00 (0.96 - 26.11) 0.06 7 43.8% 8.56 (0.88 - 83.06) 0.06 
Histology + IIF + ELISA - 31 7 22.6% 1  6 19.4% 1  1 3.2% 1  
+ 12 10 83.3% 17.14 (2.91 - 100.82) 0.002 8 66.7% 8.33 (1.79 - 38.71) 0.007 7 58.3% 42.00 (4.20 - 419.4) 0.001 
unless otherwise specified, by using univariate generalized linear models with repeated measure design where appropriate and logit link function; * 
Continuity corrected OR. Pearson’s Χ2 test was used to assess significance. 
 
